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Role of Prostaglandin E 2 in 
Cholinergic-Mediated Glycoprotein 
Synthesis in Canine Antrum 
KENJI YOSHIMURA, MD, EUGENE R. KRAUS, MS, SHUYA SHIMAKURA, MD, 
JAMES M. SCHEIMAN, MD, and C. RICHARD BOLAND, MD 
We studied the mechanism o f  cholinergic stimulation o f  mucin synthesis in canine antral 
explants, including the role o f  PGE 2 as an intermediate messenger. Isolated antral 
mucosa was incubated with 10 -5 M carbachol (Cb), 10 -s  M indomethacin (IND), 10 -s  M 
pirenzepine (PZ), 10 -5 M Cb + 10 -5 M PZ, 10 -5 M Cb + 10 -5 M I N D ,  and 10 -5 M I N D  
+ PGE2 (10 -e, 10 -7 and 10 -6 M) in the presence or absence of[3H]glucosamine. After 24 
hr, total glycoprotein synthesis was quantitated by Sepharose-4B chromatography and by 
10% TCA/I%PTA precipitation with lipid extraction. PGE 2 released into the media was 
measured by radioimmunoassay (RIA). Cb significantly increased total glycoprotein 
synthesis and produced a significant increase in PGE 2 release. The increase in glycopro- 
tein synthesis and the release o f  PGE 2 was blocked by the addition o f  muscarinic 
antagonist PZ. The addition o f  IND significantly inhibited glycoprotein synthesis and 
almost entirely suppressed PGE 2 secretion. IND also inhibited the effect o f  Cb on 
glycoprotein synthesis and PGE 2 release. Moreover, PGE 2 (10 -6 and lO-7 M) significantly 
increased the glycoprotein synthesis in the canine stomach. This suggests the coordinate 
participation o f  PGE2-releasing cell population in modulation o f  glycoprotein synthesis in 
gastric mucosa. 
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Acetylcholine, an important mediator of gastric 
acid secretion (l, 2), has been shown by many 
laboratories to stimulate mucin secretion in the 
stomach (3-6). Coceani et al (7) have shown that 
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cholinergic stimulation also significantly increased 
the release of prostaglandins (PGs), and that scopo- 
lamine completely suppressed the release of PGs 
induced by parasympathetic nerve stimulation. Sei- 
del et al (8) have reported that intact vagal innerva- 
tion is necessary for a mild irritant such as 30% 
ethanol to mediate the formation of mucosal PGs in 
the rat stomach. Moreover, Bickel and Kauffman 
(9) have demonstrated that PGE 2 increases gel 
mucus thickness in the stomach, and Seidler and 
coworkers (5, 10) have reported that both endoge- 
nous and exogenous prostaglandins stimulate gly- 
coprotein secretion. However, the mechanism by 
which cholinergic agonists stimulate mucin secre- 
tion and their role in mucin synthesis, if any, 
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remains unclear. In the present  study, we examined 
mucin synthesis induced by a cholinergic agonist in 
canine antral explants,  focusing on the role of  PGE2 
as a possible intermediate messenger.  
MATERIALS AND METHODS 
Reagents. Surital (thiamylal sodium) was obtained from 
Parke-Davis (Morris Plains, New Jersey). Gentamicin was 
obtained from Flow Laboratories, Inc. (McLean, Virgin- 
ia). DME (Dulbecco's modified Eagle's medium)-F-12 
(1:1) tissue culture medium with L-glutamine and 15 mM 
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic 
acid), sodium bicarbonate, carbachol (carbamylcholine 
chloride), pirenzepine dihydrochloride, indomethacin (1- 
[p-chlorobenzoyl]-5-methoxy-2-methylindole-3-acetic 
acid) crystalline, prostaglandin E 2 ([5Z, 1 let, 13E, 15S]- 
ll,15-dihydroxy-9-oxoprosta-5,13-dien-l-oic acid) and 
phosphotungstic acid (FrA) were purchased from Sigma 
Chemical Company (St. Louis, Missouri); trichloroacetic 
acid (TCA) from Fisher Scientific (Livonia, Michigan); 
D-[6-3H]glucosamine hydrochloride from Amersham Cor- 
poration (Arlington Heights, Illinois); diethyl-ether from 
Mallinckrodt Inc. (Paris, Kentucky); 100% ethyl alcohol 
from Midwest Grain Products Co. (Weston, Missouri); 
Safety-Solve from Research Products International Corp. 
(Mount Prospect, Illinois). 
Tissue Culture. The stomachs were excised immedi- 
ately after conditioned mongrel dogs were anesthetized 
with 5 ml of 2% Surital. The muscular layer was dissected 
from the antrum, and the mucosal layer was cut into equal 
2 x 2-ram pieces using razor blades mounted at 2-mm 
intervals on a cutting frame. Preliminary studies revealed 
that this method provided mucosal explants of uniform 
mass and geometry for culture. Ten tissue pieces were 
placed in each plastic culture well (diameter 35 mm) with 
2 ml of medium consisting of DME/FI2 (1:1), L-gluta- 
mine, 15 mM HEPES, 7.5% fetal bovine serum (FBS), 
7.5% heat-inactivated dog serum, and 0.05 mg/ml genta- 
micin (11). We added 10 -5 M carbachol (Cb), 10 -5 M 
pirenzepine (PZ), 10 -5 M indomethacin (IND), 10 -5 M 
Cb + 10 -5 M PZ, 10 -5 M Cb + 10 -3 M IND + PGE z 
(10-8-10 -6 M) tO individual wells, and used phosphate- 
buffered saline (PBS) as a control additive. The doses of 
each agent were selected based upon prior experiments 
that indicated a maximal increase in mucin synthesis by 
isolated canine mucosal cells in response to 10 -5 M 
carbachol (JM Scheiman, ER Kraus, and CR Boland, 
unpublished data). The explants were incubated in the 
presence of 5 i~Ci/well D-[1,6--3H]/giucosamine at 37 ~ C 
under 5% CO2-95% Air for 24 hr. Wells were also 
maintained in the absence of [3H]glucosamine for the 
measurement of PGE2. 
Assessment of Glycoprotein Synthesis. At the end of the 
period of incubation, media and tissue fragments were 
harvested together. After homogenization and sonication, 
they were centrifuged at 100,000g at 4~ for 1 hr to 
remove cellular debris. The supernatant was collected, 
and the glycoprotein was quantitated as follows: Two 
methods were used in an attempt to sensitively and 
specifically measure mucin. Newly synthesized mucin 
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was metabolically labeled with [3H]glucosamine; one 
method relied upon the high molecular weight of mucin, 
and the other relied upon the ability to acid precipitate all 
proteins and glycoproteins. Our laboratory has used 
column chromatography extensively to purify gastric 
mucins; however, this does not remove noncovalently 
associated lipids that migrate with the mucins (11). Acid 
precipitation permits the isolation of proteins and glyco- 
proteins, and, moreover, permits the extraction of non- 
covalently bound lipids. Unfortunately, this technique 
may also measure nonmucin glycoproteins, which make 
up a small percentage of the glycoproteins produced by 
these cells. For method I, 1 ml of each supernatant was 
applied to a Sepharose-CL-4B column (1.5 x 50 cm) 
equilibrated in PBS and eluted at 20 ml/hr. The void 
volume was pooled, and 3H radioactivity was counted by 
liquid scintillation counting (12). For method II, the 
supernatant was precipitated with 10% TCA and 1% PTA 
at 4 ~ C overnight. Then, the samples were centrifuged at 
500g for 25 min, and the pellets were resuspended by 
sonication. Each pellet was washed three times with 10% 
TCA/I% PTA and twice with ether-ethanol (3:1). The 
pellets were dissolved in 2 ml of 0.6 M KOH and 3H 
radioactivity was measured (5). 
Measurement of Prostaglandin E 2. Fifty microliters of 
media was collected from each unlabeled well before (ie, 
immediately after placement in culture) and 24 hr after the 
administration of test agent and immediately frozen at 
-70  ~ C. PGE2 in media was quantitated by radioimmu- 
noassay (RIA) in the University of Michigan Diabetes 
Center, Ligand Core Laboratory (13). The PGE2 antibody 
was purchased commercially from Cayman Chemical 
Company (Ann Arbor, Michigan). Cross-reactivities with 
other prostaglandins are as follows: 15-keto-PGE 2 -  
9.2%, and PGE1--5%; cross-reactivities were less than 
0.2% for the following prostaglandins-PGA1, PGB1, 
PGB2, PGD 2, PGFI,,, 6-keto PGFl~ PGF2, . 13,14- 
dihydro-15-keto-PGF2~, and thromboxane B2 (manufac- 
turer's specifications). 
Statistical Analysis. The results are expressed as means 
--+ SE. N is the number of experiments performed on 
different dogs, although multiple measurements were 
carded out on each individual canine stomach. Statistical 
analysis was carded out with the Student's t test. P 
values of less than 0.05 were considered to be significant. 
RESULTS 
The results of  each assay are expressed as a 
percentage of  control  wells in Figures 1, 3, and 4, 
and as a percentage of  Cb-treated wells in Figures 2 
and 5. 
Glyeoprotein Synthesis. Glycoprotein  synthesis 
measured by method I was termed V0 (for void 
volume glycoprotein) and that by method II was 
termed Ppt (for acid-precipitated glycoprotein). The 
radioactivity in the 6 ml void volume peak (V0) 
under basal conditions of  culture was 4335 --- 605 
cpm. Using the Ppt method in which the total 
glycoprotein faction was measured,  21,944 --+ 1,345 
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Fig 1. Mucin synthesis in response to 10 -~ M indomethacin 
(IND), 10 -3 M pirenzepine (PZ), and 10 -5 M carbachol (Cb) 
measured by Sepharose-4B columns (method I--Vo) and glyco- 
protein precipitation (method II--Ppt) using 10% TCA/I%PTA 
and lipid extraction. Note the scale and zero line on the y axis. 
The values are expressed as a percentage of control wells. (N = 
7; NS = not significant, **P < 0.01, ***P < 0.001, compared 
with control.) 
cpm were obtained under basal conditions of cul- 
ture. 
As shown in Figure l, 10 -5 M Cb significantly 
increased glycoprotein synthesis to 146 -+ 11% of 
control (P < 0.001) as V0, and 129 -+ 11% (P < 0.01) 
as Ppt. The addition of 10 -5 M IND significantly 
inhibited basal glycoprotein synthesis to 72 -+ 5% as 
Vo (P < 0.001) and 89 - 25 as Ppt (P < 0.01). PZ, 
10 "s M, produced a slight stimulation in glycopro- 
tein synthesis as Ppt (109 -+ 4%, P < 0.01, but not 
as V 0. 
As shown in Figure 2, IND significantly reduced 
the effect of Cb on glycoprotein synthesis (V 0 = 74 
- 9%, P < 0.05, Ppt = 80 + 8%, P < 0.05). In like 
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Fig 2. The effect of 10 -3 M I N D  and 10 -3 M PZ on 10 -3 M 
carbachol-induced mucin synthesis measured by method I (Vo) 
and method II (PP0. Note the scale and zero lirie on the y axis. 
The values are expressed as a percentage of carbachol-treated 
wells. (N = 7; *P < 0.05, **P < 0.01, ***P < 0.001, compared 
with the carbachol-treated wells.) 
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Fig 3. The effect of PGE 2 (10 -8 M to 10 -6 M) on 10 -5 M 
IND-treated mucin Synthesis measured by method I (Vo) and 
method II (PP0. Note the scale and the zero line on the y axis. 
The values are expressed as a percentage of control wells. (N = 
4; NS = not significant, *P < 0.05, compared with the IND- 
treated wells.) 
manner, PZ also decreased the effect of Cb on 
glycoprotein synthesis to 73 -+ 8% (P < 0.01) as V 0 
and to 78 _ 5% (P < 0.001) as Ppt. 
As shown in Figure 3, 10 -6 M PGE2 significantly 
restored glycoprotein synthesis in the presence of 
an inhibitory concentration of IND (10 -5 M), when 
measured as either V o (P < 0.05, compared with the 
IND-treated wells) or Ppt (P < 0.05). PGE2, 10 -7 
M, significantly restored glycoprotein synthesis 
compared to IND alone, but only when measured as 
V0 (P < 0.05). 
Prostaglandin E2 Release. The basal concentra- 
tion of PGE2 after 24 hr in culture was 43,178 - 
6113 pg/ml of media. As shown in Figure 4, 10 -5 M 
Cb significantly increased PGE2 release to 229 -+ 
18% of control wells (P < 0.001). IND, 10 -5 M, 
caused a near-complete suppression of PGE2 re- 
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Fig 4. PGE 2 release in response to 10 -5 MIND,  10 -5 M PZ, and 
10 -s  M Cb measured by radioimmunoassay (RIA). Note that the 
scale and zero line are different from those in Figures 1-3. The 
values are expressed as a percentage of control wells. (N = 6; 
NS = not significant, ***P < 0.001, compared with PBS con- 
trol.) 
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Fig 5. The effect of 10 -5 M IND and 10 -5 M PZ on 10 -5 M 
Cb-induced PGE2 release by the explants of canine gastric 
antrum measured by radioimmunoassay (RIA). The values are 
expressed as a percentage of 10 -5 M carbachol-treated wells. (N 
= 7; ***P < 0.001, compared with the Cb-treated wells.) 
lease to 5 --- 3% of control (P < 0.001). PZ, 10 -5 M, 
failed to induce a significant change in PGE2 re- 
lease. 
As shown in Figure 5, the addition of 10 -5 MIND 
suppressed the effect of 10 -5 M Cb on PGE z release 
to 1 --- 1% (P < 0.001) of Cb-treated wells. PZ, 10 -5 
M, also significantly inhibited the PGE2 release 
stimulated by Cb to 41 _+ 10% (P < 0.001) of that 
observed in Cb-treated wells. 
DISCUSSION 
The stimulant effect of the cholinergic agents on 
mucin synthesis or secretion has been reported 
from several laboratories. Gerard et al (4) have used 
histochemistry and incorporation of 35S into gastric 
epithelium to show that urecholine increased the 
apparent synthesis and secretion of mucus by fun- 
dic crypt cells and antral pyloric glands in vivo. 
Vagne and Perret (6) have demonstrated that the 
secretion of fucose- and galactose-containing gas- 
tric juice glycoconjugates was stimulated by carba- 
chol. In the present study, [3H]glucosamine incor- 
poration into antral tissues and new glycoprotein 
synthesis were significantly stimulated by the addi- 
tion of carbachol to cultured explants, which is 
similar to the findings of Seidler and Sewing on 
glycoprotein secretion (5). The dose of carbachol 
used to stimulate mucin synthesis (10 -5 M) may be 
pharmacological rather than physiological. How- 
ever, it is very difficult to know what constitutes a 
physiological concentration of a neurocrine or para- 
crine substance, since unexpectedly high concen- 
trations may be achieved at the target cell mem- 
branes. We have shown maximal stimulation of 
mucin synthesis by cultured canine gastric mucous 
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cells by carbachol 10 -6 M to 10 -5 M, which is 
inhibitable by 10 -4 M atropine (unpublished data, 
manuscript submitted). 
Various results have been reported for the effects 
of indomethacin on gastric mucous cell function. 
Some authors have reported that indomethacin de- 
creased apparent gastric mucus secretion and the 
amount of carbohydrate in secreted "mucosub- 
stances" (10, 14) and that it reduced the viability of 
mucosal cells (15). In contrast, others have reported 
that the mucus content of antral mucosa showed no 
change during indomethacin therapy (16) and that 
indomethacin did not affect the viability of isolated 
gastric cells (17). Our present study has shown that 
indomethacin significantly decreased glycoprotein 
synthesis, and the effect was reversed by exoge- 
nous PGE2 replacement. These discrepancies might 
be due to differences in experimental conditions but 
appear to reflect that the influence of indomethacin 
on mucous cells is not direct. 
Prostaglandins (PGs) produced by the stomach 
have been shown to stimulate all recognized muco- 
sal defense factors, including gastric and duodenal 
bicarbonate secretion, the production and release of 
mucus, surfactant lipid production and release with 
mucin (11), and they may have trophic effects on 
the gastric mucosa (18). It has been reported that 
both endogenous and exogenous PGE 2 stimulated 
glycoprotein secretion (5, 10) and that PGE 2 caused 
a significant increase in mucous gel thickness (9, 
19). Offerhaus et al (20) have found that the increase 
in mucosal thickness after treatment with PGE2 did 
not seem to be caused by enhanced proliferative 
activity, but rather by retarded senescence, espe- 
cially of the foveolar cell layer. It has been shown 
that PGE2 had a direct cellular "cytoprotective" 
action on gastric mucosal cells (15, 17). It has been 
recently reported that gastric mucosa had specific 
receptors for PGE 2 and that receptor binding was an 
important initial step in PGE2-mediated cellular 
responses in the stomach (21). 
Wollin et al (22) have reported that the adenylate 
cyclase activity was stimulated by both PGs and 
histamine in fundic mucosa, but only by PGs in 
antral mucosa, and that histamine and PGs stimu- 
lated two different adenylate cyclase systems. Soil, 
Wollin, and their colleagues (23, 24) have shown 
that PGE 2 stimulated the production of cyclic AMP 
by nonparietal cells. Heim et al (25) have recently 
reported that PGE 2 stimulated glycoprotein synthe- 
sis by pig gastric mucous cells. Our present study 
has shown that PGE2 significantly increased the 
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glycoprotein synthesis suppressed by 10 -5 M indo- 
methacin at a dose of 10 - 6  M and 10 -7  M. How- 
ever, exogenous PGE2 restored glycoprotein syn- 
thesis to a level slightly less than measured in 
control tissues. This might indicate that other PGs 
coordinately regulate glycoprotein synthesis or that 
indomethacin reduces the viability of mucous cells. 
The present work demonstrates that the glyco- 
protein synthesis stimulated by carbachol was sig- 
nificantly reduced by both indomethacin and piren- 
zepine. This indicates that both PGs and muscarinic 
receptors participate in the stimulus-response 
mechanism of Cb. However, as we and other au- 
thors (26, 27) have shown, the M1 antagonist piren- 
zepine alone does not suppress glycoprotein syn- 
thesis.  Nakamura  et al (28, 29) have used 
[3H]pirenzepine and autoradiography to show that 
pirenzepine-binding sites are localized predomi- 
nantly on parietal cells, chief cells, and capillary 
endothelium and that surface mucous and mucous 
neck cells had fewer pirenzepine binding sites. 
They have also suggested that parietal and chief 
cells possessed low-affinity Ml-muscarinic recep- 
tors, while the perivascular plexuses have high- 
affinity receptors. On the other hand, Lundell (30) 
has shown that acetylcholine stimulated histamine 
formation through muscarinic receptors on mast 
cells in a dose-dependent manner. Soil (2) has 
demonstrated that parietal cells account for most of 
the increase in oxygen uptake produced by expo- 
sure to gastric secretagogues in fundic isolated cell 
fractions. Thus, it is not likely that mucous and 
mucous neck cells have the same muscarinic recep- 
tors as parietal cells (1). Pirenzepine at a dose of 
10 -5 M may have a nonspecific muscarinic effect 
(ie, may not be M1 selective), so the precise defi- 
nition of the receptor subtype remains to be proven. 
It has been shown that cholinergic nerve stimu- 
lation and carbachol stimulate the release of PGE2 
in the rat stomach (7) and that vagotomy prevents 
adaptive cytoprotection to the gastric mucosal in- 
jury induced by ethanol (8). Postius et al (31) have 
suggested that more PGE2 is produced by parietal 
than by mucosal or chief cells; moreover, Arakawa 
et al (17) have shown that surface epithelial cells 
predominantly produce 6-keto-prostaglandin FI~ 
and thromboxane B2, rather than PGE 2. In the 
present work, carbachol increased PGE2 release to 
a value more than twice the control value and 
significantly stimulated glycoprotein synthesis. The 
stimulation of PGE 2 release by carbachol was sup- 
pressed almost completely by the addition of indo- 
methacin and was reduced to less than half by the 
addition of pirenzepine. This indicates the obliga- 
tory role of muscarinic receptors as an intermediate 
PGEE-releasing cell and suggests the participation 
of an additional cellular species in the regulation of 
mucus production in the intact stomach. 
Seidler and Sewing (5) have demonstrated that 
cholinergic stimulation of mucus secretion is ac- 
companied by an increase in intracellular Ca 2+, but 
that forskolin and PGE2 stimulate mucus secretion 
by independent mechanisms. In light of this, it may 
be suggested that there are at least two mechanisms 
by which mucin synthesis is induced by acetylcho- 
line in the stomach. One requires PGE2-releasing 
cells that have muscarinic receptors, which could 
include capillary endothelial cells or mast cells. In 
fact, Chen et al (32) have demonstrated that mac- 
rophages and capillary endothelial cells are the 
major producers of PGE2 in the canine fundus. 
PGE 2 may activate adenylate cyclase and stimulate 
cAMP production in mucous cells through their 
specific receptors, stimulating mucin synthesis. In 
addition, nonspecific, low-affinity muscarinic recep- 
tors on mucus cells may function through a second 
mechanism to increase intracellular calcium and 
independently stimulate mucin synthesis and the 
secretion of mucus. The role of multiple agonists 
utilizing independent second messengers has been 
well demonstrated in the regulation of acid secre- 
tion by parietal cells (2, 23). Although PGs inhibit 
secretory function in parietal cells through an inter- 
action with the G(i) subunit of the transmembrane 
signal transduction mechanism (33), the intracellu- 
lar mechanism of mucous cell response to PGs is 
not well understood. 
In summary, we have demonstrated that the 
stimulation of glycoprotein synthesis by a choliner- 
gic agonist may be inhibited by either a muscarinic 
antagonist (possibly MI) or by inhibiting PG pro- 
duction. This suggests that PGs serve as obligatory 
intermediate messengers in the mediation of cholin- 
ergic stimulation of mucous cell function. The in- 
tracellular events that mediate the post-PG re- 
sponse remain to be elucidated. 
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